Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles (PARKADD)
Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles.
This study is composed of a main study and an ancillary one. The objective of the main study is to define, on the psychopathological, neurological, pharmacokinetic and genetic plan, the predictive factors for developing a behavioural addiction (BA) secondarily to the dopaminergic treatment, associated or not to a dopamine dysregulation syndrome (DDS), in patients with Parkinson's disease.
3 particular profiles of patients will be established:
- BA- : no secondary behavioural addiction
- BA+/DDS-: secondary behavioural addiction, without dopamine dysregulation syndrome
- BA+/DDS+: secondary behavioural addiction, with dopamine dysregulation syndrome
We wish in particular:
- To differentiate, among the BA+ subjects, those for who is a DDS from those for who we can evoke a side effect of the dopaminergic treatment
- To demonstrate that the BA+/DDS- subjects present pharmacokinetic particularities causing the occurrence of the BA.
- To clarify the possible relationship between the dosage and the pharmacodynamics of the treatment (especially that of pramipexole) in one hand, and the developing of BA in the other hand.
- Demonstrate that the subjects BA + / DDS- are individually genetic vulnerability (related to the dopamine system), originally from the occurrence of the BA.
This study has several levels of evaluation, we chose describe the methodology of the study in 3 axis : Psychopathology axis, Neurological axis and pharmacokinetic axis.
The pharmacokinetic aspects will be studied only on a part of the sample, in an ancillary study centered on the pharmacokinetic of the pramipexole (in its immediate release form).
研究概览
详细说明
This is a monocentric study with a recruitment period comprised between October 2012 and April 2016. The recruitment occurs during the consultations in the service of neurology. If the subjects are eligible, the study is proposed to them, and an evaluation is fixed in the next days. This evaluation consists in an individual face-to-face interview based on standardized and semi-structured questionnaires, during approximately one and a half hour. It's focused on the different characteristics of Parkinson's disease, and on psychiatric and addictive co morbidities. The evaluation is completed by a set of self-administered questionnaires focused on impulsivity and Attention Deficit Hyperactivity Disorder (ADHD).
For the 80 patients participated to the ancillary study only, a blood sample will be realized when the patient will arrived, just before the intake of his treatment (to obtain the residual plasmatic concentration). A second sample will be realized at a different time for each patient, to cover the entirety of the kinetic between 2 intakes of pramipexole (immediate release form) via the entire sample. The second blood sample will be realized four hours after the first one at the most. After this second sample, the patient will have completed his participation to the study.
Secondly, monitoring including a self-questionnaire booklet and a saliva sample will be offered to all patients who completed the initial visit.
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Nantes、法国
- Nantes university hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Main study
Inclusion criteria:
- To be 18 years old or more (both genders)
- To have idiopathic Parkinson's disease, without important cognitive troubles, treated by usually prescribed drugs
- To have a treatment established since 6 months at least
Exclusion criteria:
- To be under tutelage (a French protecting measure for persons with altered judgement)
- To have a secondary Parkinson's disease
- To have received a chirurgical treatment for Parkinson's disease
- To present obvious cognitive disturbances
Ancillary study (pharmacokinetic axis) :
Inclusion criteria:
- The same as the main study
- To have a treatment by pramipexole in the immediate release form
Exclusion criteria:
- The same as the main study
- Association of the pramipexole with others molecules
- To use to have a behavioural addiction resolved by a diminution of the dosage before the study
学习计划
研究是如何设计的？
设计细节
- 主要用途：诊断
- 分配：非随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：BA-
Patient with no secondary behavioural addiction
|
Summons of patients and filling questionnaire.
|
|
实验性的：BA+/DDS-
Patients with secondary behavioural addiction, without dopamine dysregulation syndrome
|
Summons of patients and filling questionnaire.
|
|
实验性的：BA+/DDS+
Patients with secondary behavioural addiction and dopamine dysregulation syndrome
|
Summons of patients and filling questionnaire.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
|---|---|
|
Psychopathological axis : score of sensation seeking (S Score) of the impulsivity questionnaire "UPPS"
|
This choice is founded on the fact that patients suffering of DDS are described as being impulsive, misusing their anti-parkinsonism treatment in the purpose of stimulate themselves, suggesting they have a high level of sensation and novelty seeking.
|
|
Pharmacological axis : Area under the curve of the pramipexole concentration
|
Area under the curve of the pramipexole concentration in function of the time between 2 intakes of pramipexole.
|
|
Neurological axis : Unified Parkinson's Disease Rating Scale (UPDRS) III score
|
UPDRS III score, with axial under-score in ON and OFF DOPA (Parkinson's disease severity)
|
|
Genetic axis : distribution of allele frequencies and genotypic
|
Distribution of allele frequencies and genotypic
|
次要结果测量
结果测量 |
措施说明 |
|---|---|
|
Treatments except the anti-parkinsonism ones
|
Psychopathological axis
|
|
drug misuse
|
Psychopathological axis
|
|
addiction and punding antecedents
|
Psychopathological axis
|
|
ADHD antecedents
|
Psychopathological axis
|
|
impulsivity profile
|
Psychopathological axis
|
|
Age of onset of the Parkinson's disease
|
Neurological axis
|
|
stage and form of the Parkinson's disease
|
Neurological axis included dyskinesia and involuntary abnormal movements
|
|
time course of Parkinson's disease
|
Neurological axis
|
|
family history of Parkinson's disease
|
Neurological axis
|
|
anti-parkinsonism treatments
|
Neurological axis
|
|
Residual plasmatic concentration of the pramipexole
|
Pharmacological axis The data of the pharmacological axis are measured after analyzes of the blood samples collected in that evaluation, only for the 80 patients participated to the ancillary study.
|
|
median pharmacokinetic parameters of pramipexole
|
Pharmacological axis The data of the pharmacological axis are measured after analyzes of the blood samples collected in that evaluation, only for the 80 patients participated to the ancillary study.
|
|
study of the hepatic and renal functions
|
Pharmacological axis The data of the pharmacological axis are measured after analyzes of the blood samples collected in that evaluation, only for the 80 patients participated to the ancillary study.
|
|
Physiopathological covariates
|
Pharmacological axis age, gender, weight, creatinine and prothrombin rates The data of the pharmacological axis are measured after analyzes of the blood samples collected in that evaluation, only for the 80 patients participated to the ancillary study.
|
合作者和调查者
调查人员
- 首席研究员：Marie GRALL-BRONNEC、Nantes UH
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.